Literature DB >> 7398735

Absorption of digoxin from a new microencapsulated formulation.

B Bergdahl, C Bogentoft, U E Jonsson, J O Magnusson.   

Abstract

The absorption of digoxin from two capsule preparations containing a large number of small, enteric-coated granules of the glycoside (0.38 mg) was compared with that of the same amount from ultrarapidly dissolving commercial tablets. Eight volunteers were studied during steady state conditions. Digoxin concentrations in plasma and urine were measured by radioimmunoassay. Peak plasma concentrations of digoxin were significantly (p < 0.01) delayed after taking the capsules (2.6 +/- 1 h and 2.6 +/- 0.9 h, mean +/- SD) as compared to the tablets (1.3 +/- 0.7 h). The peak concentrations produced by the capsules were 3.1 +/- 1.0 and 2.6 +/- 1.1 nmol/l; only the latter was significantly (p less than 0.05) lower than after the tablets (3.4 +/- 1.0 nmol/l). Areas under the plasma concentration-time curves during a 24 h dosage interval were similar for the three preparations, and so was the 24 h urinary excretion of digoxin, which averaged 60-63% of the daily dose. Thus, this particular enteric coating of digoxin delayed absorption without reducing the amount absorbed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398735     DOI: 10.1007/bf00570162

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Isolation and quantitation of picomole quantities of digoxin, digitoxin and their metabolites by high-pressure liquid chromatography.

Authors:  M C Castle
Journal:  J Chromatogr       Date:  1975-12-24

2.  Absorption of enteric and non-enteric coated prednisolone tablets.

Authors:  B Hulme; V H James; R Rault
Journal:  Br J Clin Pharmacol       Date:  1975-08       Impact factor: 4.335

3.  Bioavailability of digoxin from tablets. IV. Urinary excretion of digoxin during multiple dose treatment.

Authors:  L Nyberg; K E Andersson; P O Fagerström
Journal:  Acta Pharm Suec       Date:  1977

4.  Kinetics of digoxin stability in aqueous solution.

Authors:  L A Sternson; R D Shaffer
Journal:  J Pharm Sci       Date:  1978-03       Impact factor: 3.534

5.  Bioavailability of digoxin from tablets. III. Availability of digoxin in man from preparations with different dissolution rate.

Authors:  L Nyberg; K E Andersson; A Bertler
Journal:  Acta Pharm Suec       Date:  1974-11

6.  Cleavage of glycosidic bonds of digoxin and derivatives as function of pH and time.

Authors:  J Kuhlmann; U Abshagen; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

7.  Superior bioavailability of digoxin solution in capsules.

Authors:  G I Mallis; D H Schmidt; J Lindenbaum
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

8.  Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms.

Authors:  C Bogentoft; I Carlsson; G Ekenved; A Magnusson
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

9.  Transient cardiac arrhythmias after single daily maintenance doses of digoxin.

Authors:  V Manninen; P Reissell; E Paukkala
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

10.  Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules.

Authors:  M Alpsten; C Bogentoft; G Ekenved; L Sölvell
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  5 in total

1.  Fasting and postprandial absorption of digoxin from a microencapsulated formulation.

Authors:  B Bergdahl; C Bogentoft; U E Jonsson; J O Magnusson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Metabolism of digoxin after oral and intrajejunal administration.

Authors:  J O Magnusson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  Bioavailability of indomethacin from two multiple-units controlled-release formulations.

Authors:  H Bechgaard; R R Brodie; L F Chasseaud; P Houmøller; J O Hunter; P Siklos; T Taylor
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Metabolism of digoxin and absorption site.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; U E Jonsson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

5.  Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; S Gustafsson; U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.